Story

Rumble Secures $13.7B GPU Deal in Pivot to AI, Highlighting Undercovered Mid-Caps

ENTHMSVIIDZHZH-TWJAKOHI
Aug 25, 20262 min read
Rumble Secures $13.7B GPU Deal in Pivot to AI, Highlighting Undercovered Mid-Caps
Text size
Background

Video platform Rumble (NASDAQ: RUM) has secured a landmark $13.7 billion, six-year GPU services contract, marking a significant strategic pivot toward AI infrastructure and cloud services. The deal, the largest in the company's history, is with an undisclosed U.S. cloud customer and highlights a broader theme among a handful of mid-cap stocks receiving little attention from Wall Street analysts.

Rumble's AI Infrastructure Shift

Rumble has rebranded its cloud division to RUM Group and is positioning itself as a key player in the AI compute market. The company reported that the market currently values it on a media company multiple of approximately 1x enterprise value to revenue, while comparable AI compute firms trade closer to 3.5x forward revenue.

This valuation gap is central to the investment thesis. The new contract, based at its Maysville, Georgia facility, supports management's claims of significant growth potential. The company reported second-quarter revenue of $40.4 million, a 61% year-over-year increase, and has guided for third-quarter revenue between $87 million and $93 million. Currently, only one analyst officially covers the stock, according to Investing.com data.

Contrasting Biotech Narratives

Within the biotechnology sector, two other companies with limited analyst coverage offer starkly different profiles.

Sellas: The Momentum Story

Sample IUX Markets – In-articleAd

Sellas Life Sciences (NASDAQ: SLS) has experienced a dramatic rise, with its stock surging 683% over the past year. Despite the significant rally, the clinical-stage biotech firm maintains a strong financial health rating, an unusual feature for a company at its stage. With coverage from only two analysts, bulls point to potential further upside, but investors face the risk that momentum could reverse sharply on any negative developments.

ADMA: The Value Play

In contrast, ADMA Biologics (NASDAQ: ADMA) represents a potential value opportunity. The plasma-derived therapeutics company is profitable, trading at a price-to-earnings (P/E) ratio of 13.7x. However, its stock has fallen 44% over the last year. Five analysts cover the company, seeing an average upside target of 78%, suggesting the recent selloff may be overdone. The stock has shown signs of stabilizing, gaining over 16% in the past three months.

The Low-Coverage Factor

The common thread connecting these companies is their minimal analyst coverage, which can lead to market mispricing. For Rumble, it may mean its AI pivot is not fully appreciated. For Sellas and ADMA, it points to stories that are not yet widely understood by institutional investors.

While a lack of Wall Street coverage can present an opportunity for investors to get in ahead of broader market discovery, it also carries risks. These stocks often exhibit lower trading liquidity and higher volatility compared to their more widely followed peers, as sentiment can shift rapidly on limited information.

Read next

More on Stocks
Back to latest news

LATEST